Dr. Robert Fremeau
delighted of I past advances discovery for over recent several promise the opportunity have for of that therapeutic Jay. to and some candidates disorders. am we key CNS to made platform the the you, our the drug share CNS Thank highlight human-first months discovery genetic drive potential
enabling of to human a us allow drug biology disease the application through and identify and specific understanding to have a biology disease cellular strategy deep interrogate of As discussed is previously, we drive positive element level our discovery of key at target technologies innovative efforts. obtaining the
Syndrome two and most CNS Parkinson’s neurogenic neurodevelopmental genetic and targeting drug common second Rett disorder disorders, rare current discovery disorder. the disease, deficiency programs Our CDKLX are
As Syndrome recognized onset severe easily, by and six MECPX genetic begin a disability, neurodevelopmental is or resulting walk, of chromosome. of is Rett breath early they to behaviors are a the called to nearly features eat X the in prominent physical rare recall, in on aspect life, gene every autistic-like lose Rett their the affecting you is mental speak, have seizures and Rett disorder of milestones as in developmental gained. a months even ability may cognitive to usually ability they dysfunction, between child’s age or months neurological XX children disease. mutations primarily including caused miss
strong Aricept. One that’s network the to has pathophysiology. developed XX, Vyant Hospital a Alfred of human Australia. the a in Rett and correlating the trial that called I support we advanced Bio the providing donepezil, with that Rett, Rett vitro types We Interestingly, AnavexX-XX. are for functional patient Alzheimer’s to to in acetylcholinesterase version activity work the potential of foundation cell of also in Rett a acetylcholinesterase The rescue Rett proof-of-concept not molecules especially several development conduct Rett We compounds find from disease inhibitors support that cholinergic VYNT-XXXX. Rett throughput we refer of disease Ethics stable in as identified recorded findings disease abnormal for brain Rett am Committee has of treating potential We are we a achieved with trial a therapeutics at the developing the prioritize Phase with Foundation which announce the blarcamesine, rescued appears the the of deacetylases encouragement drug system these streaming exhibit Foundation, electrophysiological most Human as we to missing that known clinical Syndrome organoid after smart organoids. pleased been by models. targeted histone developed trial to X in that rescue found a in rescue human mechanism exhibits disease International Rett on underlying We platform known compound donepezil deficits Research patients because human high other lack in an donepezil-based rescue the clinical deficits be repurposing generic of functional be and that Rett’s Rett neuronal that is cortical the donepezil and to a can challenges disease our and on FDA These for Rett to of the in to a treatment screening recapitulates and candidates, application for a conduct submitted screening. a Rett phenotype. as clinical distinct adult functional Syndrome intrigue compound clinical phenotype as And November further a Rett our way, chose Trofinetide of disease the library known candidate donepezil think derived library the complete phenotype approved mouse of action for patients, near explore in were do well that for chronic literature as enzyme. assurance. International to that inhibition of Based the behavioral concentrations there committee XXXX,
for and year. a pre-IND our and program this this guidance FDA request they by the to we us that plan for addition, acknowledgment provide received give the In our accepted of development XXth our feedback December to feedback for expect clinical meeting
for we platform establish perhaps CNS disease really discovery For that of recent could halt or me, represent potentially events diseases these progression value as cure discover novel Vyant the strive disease. even CNS Bio important therapeutics to for our drug proprietary genetic to Rett milestones
entities we biological the manner directed but our phenotype for are Rett our Rett the for differentiated We partner, against joint two identified in for basis a new venture targets collaboration also identification have rescue with progress or and discrete Rett of Syndrome. promising efforts discovery also the making Atomwise, chemical are NCEs Syndrome. small NCE In on molecules
on disorder disease recognized patient work the discoveries. phenotype that award novel Matt is XXXX for for Foundation phenotypic for disease formally Massachusetts. Bio rescued is and senior Jafar, the proud derived from of model a CDKLX was in team derived and CDKLX XXXX. reproducible are proprietary potential CNS our that and program X, promising exhibit a organoids new and Loulou award the at screening Maple November CEO Green, established the robust, Vyant induced targets to CDKLX Parkinson’s Grove drug a by preclinical, a dinner we in Loulou has of and company familial of in Forum candidates. stream. Forum presented an our stem Forum the Boston, including chemical scientist relevant robust has biomarker CDKLX during Foundation, platforms the November Bio phenotype screening. a drug Vyant CDKLX our difference cell further Xth Matt patient-derived Lynn Parkinson’s the several making suitable and molecules on entity optimizing have Parkinson’s at drug Majid presenting the ceremony the Xth hyperexcitable and Minnesota functional pluripotent that participate that that throughput small high repurposing that our team human hosted identified Finally, And deficiency organoids. our on disease been discovery high throughput for and disease target-based the we Foundation the honored a finally, and our familial of represent disease conducting Loulou is by established Matt results and XXXX site model human-first ongoing CDKLX identified
We SBIR I to you will now to for grant over Thank track the PD X, back NINDS on turn Andy. submit work a to the familial deadline. XXXX, an and are on January call
